SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Codreanu Catalin)
 

Sökning: WFRF:(Codreanu Catalin) > Effectiveness of se...

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study

Christiansen, Sara Nysom (författare)
Copenhagen University Hospital
Rasmussen, Simon Horskjær (författare)
Copenhagen University Hospital
Ostergaard, Mikkel (författare)
Copenhagen University Hospital,University of Copenhagen
visa fler...
Pons, Marion (författare)
Copenhagen University Hospital
Michelsen, Brigitte (författare)
Diakonhjemmet Hospital,Copenhagen University Hospital
Pavelka, Karel (författare)
Charles University in Prague
Codreanu, Catalin (författare)
Carol Davila University of Medicine and Pharmacy
Ciurea, Adrian (författare)
University Hospital of Zurich
Glintborg, Bente (författare)
University of Copenhagen,Copenhagen University Hospital
Santos, Maria Jose (författare)
Portuguese National Programme for Respiratory Diseases (PNDR),Hospital Garcia de Orta
Sari, Ismail (författare)
Dokuz Eylül University
Rotar, Ziga (författare)
University Medical Centre Ljubljana,University of Ljubljana
Gudbjornsson, Bjorn (författare)
National University Hospital of Iceland,University of Iceland
Macfarlane, Gary J. (författare)
Relas, Heikki (författare)
Helsinki University Central Hospital
Iannone, Florenzo (författare)
University of Bari Aldo Moro
Laas, Karin (författare)
Wallman, Johan K. (författare)
Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital
van de Sande, Marleen (författare)
University of Amsterdam
Provan, Sella Aarrestad (författare)
Inland Norway University of Applied Sciences,Diakonhjemmet Hospital
Castrejon, Isabel (författare)
Hospital Gregorio Maranon,Complutense University of Madrid
Zavada, Jakub (författare)
Charles University in Prague
Mogosan, Corina (författare)
Carol Davila University of Medicine and Pharmacy
Nissen, Michael J. (författare)
Geneva University Hospital
Loft, Anne Gitte (författare)
Aarhus University Hospital
Barcelos, Anabela (författare)
NOVA University Lisbon
Erez, Yesim (författare)
Pirkmajer, Katja Perdan (författare)
University of Ljubljana,University Medical Centre Ljubljana
Grondal, Gerdur (författare)
National University Hospital of Iceland,University of Iceland
Jones, Gareth T. (författare)
Hokkanen, Anna Mari (författare)
University of Helsinki
Chimenti, Maria Sole (författare)
University of Rome Tor Vergata
Vorobjov, Sigrid (författare)
National Institute for Health Development, Estonia
Giuseppe, Daniela Di (författare)
Karolinska Institutet,Karolinska Institute
Kvien, Tore K. (författare)
Diakonhjemmet Hospital,University of Oslo
Otero-Varela, Lucia (författare)
van der Horst-Bruinsma, Irene (författare)
Radboud University Medical Center
Hetland, Merete Lund (författare)
University of Copenhagen,Copenhagen University Hospital
Ørnbjerg, Lykke Midtbøll (författare)
Copenhagen University Hospital
visa färre...
 (creator_code:org_t)
2024
2024
Engelska.
Ingår i: RMD Open. - 2056-5933. ; 10:3
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries. Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/ Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated. Remission and drug retention rates in r-axSpA versus nr-axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/ adjusted for multiple confounders). Results Overall, 1161 secukinumab-treated patients were included (r-axSpA/nr-axSpA: 922/239). At baseline, r-axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA-B27 positive and had received fewer prior biological or targeted synthetic disease-modifying antirheumatic drugs compared with nr-axSpA patients, whereas PROs were largely similar. During follow-up, crude PRO remission rates were significantly higher in r-axSpA compared with nr-axSpA patients (6 months: pain≤2: 40%/28%, OR=1.7; BASDAI≤2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r-axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr-axSpA (6 months: 11%/8%). However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates. Conclusion Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

Ankylosing
Epidemiology
Pain
Patient Reported Outcome Measures
Spondylitis
Therapeutics

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

  • RMD Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy